Gw&K Investment Management 13F: Cuts GMED Stake by $1.7M

Gw&K Investment Management recently trimmed its position in Globus Medical, Inc. (NYSE: GMED) by 21,622 shares. This adjustment brings its total holdings to 1,494,723 shares, valued at approximately $120.2 million as of the latest quarter. The change represents a 1.43% reduction in its stake.

What Changed in Gw&K's Globus Medical Position

Gw&K's recent filing shows a reduction of 21,622 shares in Globus Medical, decreasing its stake by 1.43% to a total of 1,494,723 shares. The value of these holdings is reported at about $120.2 million.

Other Institutional Activity in Globus Medical

Several other major funds also adjusted their positions in Globus Medical. BlackRock, Inc. increased its holdings by 213,321 shares, bringing its total to 10,497,414 shares worth approximately $904.5 million. Janus Henderson Group PLC added 328,217 shares, resulting in 7,623,095 shares valued at $656.8 million. Vanguard Capital Management LLC and Vanguard Portfolio Management LLC both reported their holdings, with 5,032,732 shares and 4,879,459 shares, respectively. Invesco Ltd. increased its stake by 430,249 shares to 4,316,654 shares, valued at $371.9 million, while State Street Corp added 126,527 shares, totaling 3,590,372 shares worth $309.3 million.

Globus Medical, Inc. Stock Up 6.7%

Shares of Globus Medical (NYSE: GMED) are trading around $80.39. The company has a market capitalization of about $10.91 billion, with a P/E ratio of 18.78 and a forward P/E of 15.61. Its beta is 0.95, indicating moderate volatility. The stock's 52-week range is between $51.79 and $101.40, with a 50-day moving average of $85.95 and a 200-day moving average of $80.58. Globus Medical maintains a strong current ratio of 4.56 and a quick ratio of 2.83, with a debt-to-equity ratio of 2.45.

Recent Earnings

In its most recent financial results, Globus Medical reported revenue of $3.1 billion, reflecting a growth rate of 27%. The company achieved a net margin of 18.92% and a return on equity of 13.3%. Earnings per share stood at $4.28. The next earnings release is scheduled for August 6, 2026.

Insider Buying and Selling at Globus Medical, Inc.

Notable insider transactions at Globus Medical include Davidar David selling 25,000 shares at an average price of $80.76 on June 5, 2026, and buying the same number of shares at $26.27. Ann Rhoads also bought 25,000 shares at $26.27 on June 4, 2026. EVP and Corporate Secretary Kelly Huller sold 20,000 shares at $94.50 on February 25, 2026.

Analysts Set New Price Targets

Analysts have maintained a positive outlook on Globus Medical. On May 8, 2026, RBC Capital, Wells Fargo, and Needham all maintained their 'buy' ratings, setting price targets of $120, $103, and $117, respectively. The consensus among 11 analysts is a 'buy' rating with a mean price target of $110.

About Globus Medical

Globus Medical, Inc. is a healthcare company based in Audubon, Pennsylvania, specializing in medical devices. Founded in 2003, the company develops and sells a range of products for musculoskeletal disorders, including spine and orthopedic trauma solutions. It also offers advanced technologies like the ExcelsiusGPS robotic guidance system for surgery. Under the leadership of CEO Keith W. Pfeil, the company employs about 6,000 people.

Bottom Line

Gw&K Investment Management's decision to trim its stake in Globus Medical highlights ongoing adjustments among institutional investors. While the 13F filing provides a snapshot of holdings as of the reporting period, it may not reflect current positions. Investors and analysts continue to watch Globus Medical closely due to its robust financial performance and innovative product offerings.